| Name | Title | Contact Details |
|---|
Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.
Founded in 2010, Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies.
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.
Kyowa Pharmaceutical is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.